Welcome to our dedicated page for Cardinal Health SEC filings (Ticker: CAH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cardinal Health, Inc. (NYSE: CAH) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Cardinal Health is an Ohio corporation whose common shares trade on the New York Stock Exchange under the symbol CAH, as noted in multiple Form 8-K filings. These documents give investors detailed insight into the company’s financial condition, governance, capital structure, and material events.
Cardinal Health regularly files Form 8-K current reports to announce significant developments. Recent 8-K filings include disclosures about quarterly and annual financial results, updates to fiscal 2026 non-GAAP earnings per share outlook, entry into material definitive agreements such as credit facilities and receivables purchase amendments, public offerings of notes to help fund acquisitions like Solaris Health, and the completion of those offerings. Other 8-Ks document matters such as the 2025 Annual Meeting of Shareholders and voting results on director elections, say-on-pay, and auditor ratification.
The company’s definitive proxy statement on Schedule 14A (DEF 14A) offers extensive information on corporate governance, Board composition, executive compensation, and shareholder voting items. Cardinal Health’s proxy materials describe its strategic priorities, fiscal performance highlights, Board skills and refreshment, and engagement with shareholders.
Through Stock Titan, users can review Cardinal Health’s periodic and current reports and use AI-powered tools to summarize key points from lengthy filings. These tools help explain complex sections, highlight items such as non-GAAP metrics definitions, capital markets transactions, and credit agreements, and make it easier to track themes like Specialty growth, distribution network investments, and capital allocation. The filings page also surfaces relevant exhibits, including indentures, underwriting agreements, and amendments to financing arrangements, giving a structured view of Cardinal Health’s obligations and governance framework.
Cardinal Health (CAH) director filed a Form 4 reporting a grant of 1,067 restricted share units on November 5, 2025 at $0. Following the award, the reporting person beneficially owns 32,264 shares, held directly.
The RSUs will vest on November 5, 2026, or on the date of the 2026 Annual Meeting of Shareholders if that meeting occurs earlier.
Cardinal Health (CAH) reported voting results from its 2025 Annual Meeting. Shareholders elected 12 director nominees to serve until the 2026 Annual Meeting. The advisory vote on executive compensation passed with 168,382,554 votes For, 17,271,117 Against, and 1,513,298 Abstained.
Shareholders also ratified Ernst & Young LLP as the independent auditor for the fiscal year ending June 30, 2026, with 195,705,020 For, 12,253,800 Against, and 310,216 Abstained. Director elections included standard broker non-votes of 21,102,067 across proposals where applicable.
Cardinal Health (CAH) reported a director’s equity grant. On 11/05/2025, the director acquired 1,067 common shares via a grant of restricted share units at a stated price of $0.
Following the transaction, the director beneficially owns 15,373 shares, held directly. The restricted share units will vest on November 5, 2026, or on the date of the 2026 Annual Meeting of Shareholders if that meeting occurs before November 5, 2026.
Cardinal Health (CAH) director reported an equity award on a Form 4. On 11/05/2025, the director acquired 1,067 restricted share units at a price of $0. Following the transaction, the director beneficially owned 14,848 shares, held directly.
The RSUs will vest on November 5, 2026, except that if the 2026 Annual Meeting of Shareholders occurs before that date, they vest on the meeting date.
Cardinal Health (CAH) disclosed on a Form 4 that a director received 1,067 restricted share units on 11/05/2025 at a stated price of $0. The award will vest on November 5, 2026, or on the date of the 2026 Annual Meeting of Shareholders if that meeting occurs earlier.
Following this grant, the reporting person beneficially owns 8,086 common shares, held directly. This reflects routine director equity compensation and does not indicate a sale of shares.
Cardinal Health (CAH) reported a director equity grant. On 11/05/2025, a board member acquired 1,067 restricted share units at $0, bringing directly held common shares to 4,085 after the transaction.
The grant will vest on November 5, 2026, or on the date of the 2026 Annual Meeting of Shareholders if that meeting occurs before November 5, 2026.
Cardinal Health (CAH) reported strong first‑quarter results for the period ended September 30, 2025. Revenue rose 22% to $64.0 billion, driven by branded and specialty pharmaceutical sales. GAAP operating earnings increased 18% to $668 million, while non‑GAAP operating earnings grew 37% to $857 million.
GAAP diluted EPS was $1.88 (up 11%) and non‑GAAP diluted EPS was $2.55 (up 36%), reflecting contributions from recently acquired MSO platforms and Advanced Diabetes Supply. Segment profit improved across the board: Pharma up 26% to $667 million, Global Medical up to $46 million, and Other up 60% to $166 million. GLP‑1 demand boosted sales but had limited profit impact due to mix.
Liquidity strengthened with $4.6 billion in cash and $973 million provided by operations, including $403 million in opioid‑related payments. The company issued $1.0 billion of new notes (4.5% due 2030; 5.15% due 2035), repaid $500 million of 2025 notes, and executed a $375 million accelerated share repurchase. CAH announced a definitive agreement to acquire Solaris Health for approximately $1.9 billion in cash plus an estimated $500 million in Specialty Alliance units, to be reported within the Pharma segment upon closing.
Cardinal Health, Inc. filed a current report to note that it has released financial results for the quarter ended September 30, 2025. The company issued a news release, which is furnished as Exhibit 99.1, summarizing its first-quarter performance.
The report also explains that the Chief Executive Officer and Chief Financial Officer will host a webcast at 8:30 a.m. Eastern time on October 30, 2025 to discuss the quarterly results and the outlook for the fiscal year ending June 30, 2026. A slide presentation and an audio replay of the webcast will be available on the Investors page of Cardinal Health’s website.
BlackRock Portfolio Management LLC filed a Schedule 13G reporting beneficial ownership of 11,947,456 shares (5.0%) of Cardinal Health, Inc. common stock. The firm reports sole voting power over 10,919,560 shares and sole dispositive power over 11,947,456 shares as of the event date.
The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing control. It also notes that various underlying persons have rights to dividends or sale proceeds, and no single person exceeds five percent of the outstanding common shares.
Cardinal Health, Inc. entered into a new 364-day credit agreement on October 7, 2025 with Bank of America, N.A. as administrative agent and a syndicate of lenders. The facility provides access to up to $1.0 billion of revolving credit through October 6, 2026 and replaces a similar 364-day agreement that expired from October 2024.
At the termination date, Cardinal Health may, subject to conditions in the agreement, convert any outstanding borrowings into non-revolving term loans that must be repaid one year later. The agreement includes customary representations, covenants and events of default, including a financial covenant requiring a consolidated net leverage ratio not greater than 3.75 to 1.00 as of the last day of any fiscal quarter.
The revolving credit facility may be used for general corporate purposes and backs the company’s commercial paper program. Participating financial institutions and their affiliates have previously provided, and may continue to provide, various banking and financial services to Cardinal Health for customary fees.